BYBang-Hung Yang

Bang-Hung Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bang-Hung Yang has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Landmark Multiyear Study of Alzheimer Disease: Integrating [18F]FEPPA PET Imaging With 12 Clinical Assessments for Comprehensive Disease Profiling

    by Skye Hsin-Hsien Yeh, Yung-Shuan Lin, Wei-Ju Lee, Wen-Yi Chang, Tsung-Hsun Yu, Chi-Wei Chang, Bang-Hung Yang, Ing-Jou Chen, Chyng-Yann Shiue, Nan-Jing Peng, et al.

    Purpose: This multiyear study aimed to investigate the relationship between TSPO expression and cognitive decline in Alzheimer disease (AD) using [18F]FEPPA PET imaging. We integrated this imaging data with 12 comprehensive clinical measures to assess disease severity and progression in AD, mild cognitive impairment (MCI), and healthy controls (HC). Methods: A total of 39 participants, including 17 AD patients, 9 MCI patients, and 13 healthy controls, underwent [18F]FEPPA PET imaging and neuropsychological evaluations. Quantitative analysis was performed to determine the total distribution volume (VT) ratios in 8 brain regions, such as the frontal lobe, parietal lobe, and hippocampus. Cognitive function was assessed using a battery of tests, including the Mini-Mental State Examination (MMSE), Rey Auditory Verbal Learning Test (RAVLT), and Trail Making Test. Results: AD patients exhibited significantly elevated VT ratios in the frontal lobe, parietal lobe, and hippocampus compared with HC (P < 0.01). Notably, MCI patients had higher VT ratios than both HC and AD in the temporal and occipital lobes (P < 0.05), indicating early neuroinflammatory involvement. Moderate to strong correlations (R 2 values: 0.45–0.68) were observed between TSPO expression and cognitive performance. Conclusions: The findings of this study provide preliminary support for the use of [18F]FEPPA PET in assessing neuroinflammation related to cognitive decline in AD. Moreover, our results indicate that combining imaging techniques with neuropsychological assessments may offer a useful approach for monitoring disease progression and detecting early inflammatory changes in individuals with MCI.


  • Open Access

    Feasibility evaluation of middle-phase 18F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment

    by Cheng-Han Wu, Yueh-Hsun Lu, Tse-Hao Lee, Chun-Yuan Tu, Jong-Ling Fuh, Yuh-Feng Wang, Bang-Hung Yang

    Background: 18F-florbetaben (FBB) positron emission tomography (PET) scan has been widely used in research and routine clinical practice. Most studies used late-phase (scanning from 90 to 110 min after injection) FBB scans to generate beta-amyloid accumulation data. The feasibility of middle-phase scan is seldom discussed. Using the middle-phase data can shorten the patients’ waiting between the injection and scan, and hospital can acquire more flexible schedule of routine scan. Methods: Paired middle-phase (60–80 min) FBB scans and standard (90–110 min) FBB scans were obtained from 27 subjects (12 neurodegenerative dementia, 8 mild cognitive impairment, 3 normal control, and 4 patients not suffering from neurodegenerative dementia). Standardized uptake value ratios (SUVRs) were calculated and converted to centiloid (CL) scale to investigate the impact on image quantification. CL pipeline validation were performed to build an equation converting the middle-phase data into equivalent standard scans. Cohen’s kappa of binary interpretation and brain amyloid plaque load (BAPL) score were also used to evaluate the intrareader agreement of the FBB image from the two protocols. Results: The middle-phase FBB SUVR showed an excellent correlation, which provided a linear regression equation of SUVRFBB60–80 = 0.88 × SUVRFBB90–110 + 0.07, with R2=0.98. The slope of the equation indicated that there was bias between the middle and standard acquisition. This can be converted into the CL scale using CL = 174.68 × SUVR − 166.39. Cohen’s kappa of binary interpretation and BAPL score were 1.0 (PConclusions: Our findings indicate that the middle-phase FBB protocol is feasible in clinical applications for scans that are at either end of beta-amyloid spectrum, which provides comparable semiquantitative results to standard scan. Patient’s waiting time between the injection and scan can be shortened.


  • Deep learning-based denoising in projection-domain and reconstruction-domain for low-dose myocardial perfusion SPECT

    by Jingzhang Sun, Han Jiang, Yu Du, Chien-Ying Li, Tung-Hsin Wu, Yi-Hwa Liu, Bang-Hung Yang, Greta S. P. Mok


  • Open Access

    Very-Low-Dose Radiation and Clinical Molecular Nuclear Medicine

    by Chi-Jung Tsai, Kang-Wei Chang, Bang-Hung Yang, Ping-Hsiu Wu, Ko-Han Lin, Ching Yee Oliver Wong, Hsin-Lun Lee, Wen-Sheng Huang

    Emerging molecular and precision medicine makes nuclear medicine a de facto choice of imaging, especially in the era of target-oriented medical care. Nuclear medicine is minimally invasive, four-dimensional (space and time or dynamic space), and functional imaging using radioactive biochemical tracers in evaluating human diseases on an anatomically configured image. Many radiopharmaceuticals are also used in therapies. However, there have been concerns over the emission of radiation from the radionuclides, resulting in wrongly neglecting the potential benefits against little or any risks at all of imaging to the patients. The sound concepts of radiation and radiation protection are critical for promoting the optimal use of radiopharmaceuticals to patients, and alleviating concerns from caregivers, nuclear medicine staff, medical colleagues, and the public alike.


  • Open Access

    Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer’s Disease

    by Yi-An Chen, Cheng-Hsiu Lu, Chien-Chih Ke, Sain-Jhih Chiu, Chi-Wei Chang, Bang-Hung Yang, Juri G. Gelovani, Ren-Shyan Liu

    Epigenetic regulation by histone deacetylase (HDAC) is associated with synaptic plasticity and memory formation, and its aberrant expression has been linked to cognitive disorders, including Alzheimer’s disease (AD). This study aimed to investigate the role of class IIa HDAC expression in AD and monitor it in vivo using a novel radiotracer, 6-(tri-fluoroacetamido)-1-hexanoicanilide ([18F]TFAHA). A human neural cell culture model with familial AD (FAD) mutations was established and used for in vitro assays. Positron emission tomography (PET) imaging with [18F]TFAHA was performed in a 3xTg AD mouse model for in vivo evaluation. The results showed a significant increase in HDAC4 expression in response to amyloid-β (Aβ) deposition in the cell model. Moreover, treatment with an HDAC4 selective inhibitor significantly upregulated the expression of neuronal memory-/synaptic plasticity-related genes. In [18F]TFAHA-PET imaging, whole brain or regional uptake was significantly higher in 3xTg AD mice compared with WT mice at 8 and 11 months of age. Our study demonstrated a correlation between class IIa HDACs and Aβs, the therapeutic benefit of a selective inhibitor, and the potential of using [18F]TFAHA as an epigenetic radiotracer for AD, which might facilitate the development of AD-related neuroimaging approaches and therapies.


  • Open Access

    Mesenchymal Stem Cell-Derived Exosomes Ameliorate Alzheimer’s Disease Pathology and Improve Cognitive Deficits

    by Yi-An Chen, Cheng-Hsiu Lu, Chien-Chih Ke, Sain-Jhih Chiu, Fong-Shya Jeng, Chi-Wei Chang, Bang-Hung Yang, Ren-Shyan Liu

    The accumulation of extracellular β-amyloid (Aβ) plaques within the brain is unique to Alzheimer’s disease (AD) and thought to induce synaptic deficits and neuronal loss. Optimal therapies should tackle the core AD pathophysiology and prevent the decline in memory and cognitive functions. This study aimed to evaluate the therapeutic performance of mesenchymal stem cell-derived exosomes (MSC-exosomes), which are secreted membranous elements encapsulating a variety of MSC factors, on AD. A human neural cell culture model with familial AD (FAD) mutations was established and co-cultured with purified MSC-exosomes. 2-[18F]Fluoro-2-deoxy-d-glucose ([18F]FDG) and novel object recognition (NOR) testing were performed before/after treatment to evaluate the therapeutic effect in vivo. The AD-related pathology and the expression of neuronal memory/synaptic plasticity-related genes were also evaluated. The results showed that MSC-exosomes reduced Aβ expression and restored the expression of neuronal memory/synaptic plasticity-related genes in the cell model. [18F]FDG-PET imaging and cognitive assessment revealed a significant improvement in brain glucose metabolism and cognitive function in AD transgenic mice. The phase of neurons and astrocytes in the brain of AD mice were also found to be regulated after treatment with MSC-exosomes. Our study demonstrates the therapeutic mechanism of MSC-exosomes and provides an alternative therapeutic strategy based on cell-free MSC-exosomes for the treatment of AD.


  • Open Access

    Effect of Cerenkov Radiation-Induced Photodynamic Therapy with 18F-FDG in an Intraperitoneal Xenograft Mouse Model of Ovarian Cancer

    by Yi-An Chen, Jia-Je Li, Syue-Liang Lin, Cheng-Hsiu Lu, Sain-Jhih Chiu, Fong-Shya Jeng, Chi-Wei Chang, Bang-Hung Yang, Ming-Cheng Chang, Chien-Chih Ke, et al.

    Ovarian cancer (OC) metastases frequently occur through peritoneal dissemination, and they contribute to difficulties in treatment. While photodynamic therapy (PDT) has the potential to treat OC, its use is often limited by tissue penetration depth and tumor selectivity. Herein, we combined Cerenkov radiation (CR) emitted by 18F-FDG accumulated in tumors as an internal light source and several photosensitizer (PS) candidates with matched absorption bands, including Verteporfin (VP), Chlorin e6 (Ce6) and 5′-Aminolevulinic acid (5′-ALA), to evaluate the anti-tumor efficacy. The in vitro effect of CR-induced PDT (CR-PDT) was evaluated using a cell viability assay, and the efficiency of PS was assessed by measuring the singlet oxygen production. An intraperitoneal ES2 OC mouse model was used for in vivo evaluation of CR-PDT. Positron emission tomography (PET) imaging and bioluminescence-based imaging were performed to monitor the biologic uptake of 18F-FDG and the therapeutic effect. The in vitro studies demonstrated Ce6 and VP to be more effective PSs for CR-PDT. Moreover, VP was more efficient in the generation of singlet oxygen and continued for a long time when exposed to fluoro-18 (18F). Combining CR emitted by 18F-FDG and VP treatment not only significantly suppressed tumor growth, but also prolonged median survival times compared to either monotherapy.


  • Auto-ROIs of bone scan image using thin-plate spline with specific bone landmarks

    by Meilan Jimmy Hasugian, Wen-Chen Lin, Mei-Fen Chen, Bang-Hung Yang, Ren-Shyan Liu, Kang-Ping Lin